As Populations Age, Four Disease Burdens Reshape Global Health Planning

The world is growing older at a pace without historical precedent, yet the illnesses that once defined poorer societies have not faded away. Writing in Nature Aging, Joseph L. Dieleman of the Institute for Health Metrics and Evaluation at the University of Washington examines a provocative new statistical framing of the epidemiological transition proposed by Ashwin and colleagues, one that sorts the world’s diseases into four distinct life-stage categories and finds that aging-related diseases now constitute the dominant share of the global disease burden. The analysis arrives at a moment when policymakers, health ministries and international funders are struggling to reconcile two competing realities: populations are living longer than ever, and the infectious diseases, maternal conditions and childhood illnesses of earlier eras continue to claim lives at rates that wealthier nations once believed were behind them. The result, Dieleman argues, is a double burden of illness that most countries carry simultaneously, and one that demands a fundamental rethinking of how health systems are designed and financed.

The intellectual foundation of the new framework traces back more than half a century. In 1971, Abdel Omran published his landmark formulation of the epidemiological transition in the Milbank Memorial Fund Quarterly, describing how societies move through stages in which pestilence and famine give way to receding pandemics, and eventually to degenerative and man-made diseases as the leading causes of death. Omran’s model became one of the most cited organizing ideas in global health, shaping decades of assumptions about how mortality patterns evolve as nations develop. For generations of researchers and planners, the transition implied a kind of linear progression: as incomes rose and sanitation improved, infectious disease would recede and chronic, non-communicable conditions would take their place. The new work by Ashwin, Bloom, Lee, Piot and Scott builds directly on that lineage but departs from it in a crucial way, replacing the narrative of sequential stages with a statistical categorization that reflects the messy, overlapping reality of disease in the twenty-first century.

At the heart of the proposal is a data-driven taxonomy that assigns diseases to four categories defined by the life stages in which they exert their greatest toll. One category captures the classic afflictions of early life, including the infectious diseases, nutritional deficiencies and neonatal conditions that historically dominated mortality in low-income settings. A second encompasses injuries and other conditions that strike across the working years. A third covers diseases concentrated in later life, and the fourth, the category the authors identify as dominant, consists of aging-related diseases, conditions whose incidence rises steeply as biological aging advances. Rather than treating these categories as successive phases through which a country passes, the framework treats them as concurrent burdens whose relative weights shift with demography, development and policy. The statistical approach allows researchers to quantify how much of a nation’s disease burden falls into each category and to track how those proportions change over time, offering a more granular and actionable picture than the traditional stage-based narrative.

What the analysis reveals is striking. Aging-related diseases, a grouping that includes many of the cardiovascular conditions, cancers, neurodegenerative disorders and other chronic illnesses whose risk escalates with age, now represent the dominant category of disease burden globally. This is not simply because people are living longer, although they are; it reflects the compounding effect of demographic change on disease statistics. As the share of older adults in a population grows, conditions that cluster in later life inevitably account for a larger fraction of total illness and death. But the framework also makes clear that the other three categories have not disappeared. In much of sub-Saharan Africa and parts of South Asia, childhood infections, maternal complications and neonatal disorders remain leading causes of lost healthy years, even as non-communicable diseases surge in the same populations. The figure accompanying Dieleman’s commentary captures this tension in a single image: the world is aging, but most countries still carry all four disease burdens at once.

The persistence of the double burden is the analytical pivot of the commentary. The double burden of disease, a term long used in nutrition and global health circles to describe the coexistence of undernutrition and obesity, or of infectious and chronic disease, is here extended to the full spectrum of illness. Countries that once might have been classified as being in an early stage of the epidemiological transition are simultaneously confronting the diseases of aging, often with health systems built for neither. Dieleman points to evidence from the Global Burden of Disease enterprise, including the GBD 2023 Diseases and Injuries Collaborators’ comprehensive assessment published in The Lancet, which documents how the composition of disease burden has shifted unevenly across regions. High-income countries have largely completed the shift toward chronic disease but now face the escalating costs of multimorbidity, in which patients accumulate multiple aging-related conditions that interact and complicate treatment. Low- and middle-income countries face the harder problem of managing both ends of the spectrum with constrained budgets and thin clinical workforces.

The clustering of aging-related diseases is a central technical concern of the new framing. Unlike many infectious diseases, which follow acute episodes and either resolve or kill within weeks, aging-related conditions tend to be chronic, progressive and mutually reinforcing. Diabetes accelerates cardiovascular disease; cardiovascular disease raises the risk of dementia; sarcopenia and frailty compound the disability caused by arthritis and osteoporosis. Because these conditions cluster within individuals and accumulate over decades, their combined burden spans many years of life, generating sustained demand for continuous care rather than episodic intervention. This temporal profile has profound implications for health economics. A health system oriented toward acute treatment, with hospitals, specialists and pharmaceutical interventions organized around discrete episodes of illness, is poorly matched to a disease landscape in which the dominant conditions require decades of management, coordination across specialties and support for daily functioning outside clinical settings.

It is from this mismatch that Dieleman draws the commentary’s central policy argument: health systems must pivot from treating disease to preserving health. The phrase signals a shift in orientation from downstream intervention to upstream investment, and the authors of the underlying study, along with Dieleman, argue that such investment must begin in all life stages, not merely in old age. The rationale is grounded in the biology of aging itself. Research highlighted in the field, including the influential 2014 position statement by Kennedy and colleagues in Cell, has established that aging is a modifiable risk factor shared by many chronic diseases, and that interventions which slow biological aging processes can delay or reduce the onset of multiple conditions simultaneously. In practical terms, investments in early-life nutrition, childhood immunization, adolescent health, adult prevention of hypertension and diabetes, and the social determinants of health across the entire life course all feed into the trajectory of aging-related disease decades later. A health system that waits until patients are elderly to address these conditions has already lost much of its leverage.

This life-course perspective aligns with a growing body of policy scholarship. Work by Kuruvilla and colleagues published in the Bulletin of the World Health Organization has articulated the case for life-course approaches to health, and analyses by Jamison and colleagues in The Lancet have mapped the essential investments that countries can make at each stage of development to improve health outcomes efficiently. Studies by Bollyky and colleagues in Health Affairs have further documented how the burden of chronic disease in developing countries is intertwined with economic growth and demographic change, complicating the old assumption that prosperity automatically solves chronic disease. The new statistical framing by Ashwin and colleagues gives these arguments a sharper analytical edge by providing a common metric, the four-category disease taxonomy, against which countries can measure their current burdens, project future trajectories and prioritize investments. It also offers a way to compare nations that are at very different points in their demographic transitions without forcing them into a single linear model that may describe none of them accurately.

The implications for global health financing are considerable. Donor institutions and national governments have long organized funding streams around disease categories and life stages in silos: one budget line for child survival, another for HIV and tuberculosis, another for non-communicable diseases, another for aging and long-term care. The four-category framework suggests that these silos are not merely administratively convenient but analytically misleading, because the burdens interact and the most efficient interventions often cut across them. Dieleman’s commentary, published as a News and Views perspective in Nature Aging on 7 September 2026, does not prescribe a specific financing formula, but its message is unambiguous. As aging-related diseases become the dominant category of global illness, and as most countries continue to shoulder the infectious, maternal and childhood burdens of earlier transitions, the health systems that succeed will be those that stop treating aging populations as an afterthought and start investing in health preservation from the first years of life onward. The double burden is not a transitional inconvenience to be waited out; it is the permanent operating condition of modern global health, and policy must be built to match it.

Subject of Research: A statistical reframing of the epidemiological transition that categorizes global diseases into four life-stage groups and highlights aging-related diseases as the dominant burden

Article Title: Aging rises, yet the double burden of illness remains

Article References: Dieleman, J. L. (2026). Aging rises, yet the double burden of illness remains. Nature Aging. https://doi.org/10.1038/s43587-026-01218-8

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01218-8

Keywords: epidemiological transition, aging-related diseases, global disease burden, double burden of disease, health systems, life-course health, non-communicable diseases, demographic change, global health financing, multimorbidity, disease taxonomy, health policy